이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary

2017년 2월 16일 업데이트: Alliance for Clinical Trials in Oncology

A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)

RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

PURPOSE: This phase II trial is studying how well carboplatin given together with paclitaxel and everolimus works in treating patients with previously untreated cancer of unknown primary.

연구 개요

상태

완전한

정황

개입 / 치료

상세 설명

OBJECTIVES:

Primary

  • Evaluate the response rate in patients with previously untreated cancer of unknown primary treated with the combination of carboplatin, paclitaxel, and everolimus.

Secondary

  • Assess time to progression, overall survival, duration of response, and time to treatment failure in patients treated with this regimen.
  • Determine adverse events of this regimen in these patients.
  • Perform descriptive correlative studies to determine response of specific tumor types, identified by the Origin-FFPE test, to this regimen.

OUTLINE: This is a multicenter study.

Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Patients also receive oral everolimus once daily on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Patients' tumor tissue samples from the most recent biopsy are analyzed for correlative studies, including gene expression profiling by Origin-FFPE test.

After completion of study therapy, patients are followed up every 3 months until disease progression, and then every 6 months for up to 3 years.

연구 유형

중재적

등록 (실제)

46

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

  • 미국
    • Colorado
      • Fort Collins, Colorado, 미국, 80524
        • Poudre Valley Hospital
      • Fort Collins, Colorado, 미국, 80528
        • Front Range Cancer Specialists
    • Connecticut
      • Hartford, Connecticut, 미국, 06105
        • Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
    • Illinois
      • Moline, Illinois, 미국, 61265
      • Moline, Illinois, 미국, 61265
        • Trinity Cancer Center at Trinity Medical Center - 7th Street Campus
    • Indiana
      • Elkhart, Indiana, 미국, 46515
        • Elkhart General Hospital
      • Elkhart, Indiana, 미국, 46514-2098
        • Elkhart Clinic, LLC
      • Elkhart, Indiana, 미국, 46514
        • Michiana Hematology-Oncology, PC - Elkhart
      • Indianapolis, Indiana, 미국, 46237
        • St. Francis Hospital Cancer Care Services
      • Kokomo, Indiana, 미국, 46904
        • Howard Community Hospital
      • La Porte, Indiana, 미국, 46350
        • Center for Cancer Therapy at LaPorte Hospital and Health Services
      • Mishawaka, Indiana, 미국, 46545-1470
        • Michiana Hematology-Oncology, PC - South Bend
      • Mishawaka, Indiana, 미국, 46545-1470
        • Saint Joseph Regional Medical Center
      • Plymouth, Indiana, 미국, 46563
        • Michiana Hematology Oncology PC - Plymouth
      • Richmond, Indiana, 미국, 47374
        • Reid Hospital & Health Care Services
      • South Bend, Indiana, 미국, 46601
        • Memorial Hospital of South Bend
      • South Bend, Indiana, 미국, 46601
        • CCOP - Northern Indiana CR Consortium
      • Westville, Indiana, 미국, 46391
        • Michiana Hematology Oncology PC - La Porte
    • Iowa
      • Ames, Iowa, 미국, 50010
        • McFarland Clinic, PC
      • Bettendorf, Iowa, 미국, 52722
      • Cedar Rapids, Iowa, 미국, 52403
        • Cedar Rapids Oncology Associates
      • Cedar Rapids, Iowa, 미국, 52403
        • Mercy Regional Cancer Center at Mercy Medical Center
      • Clive, Iowa, 미국, 50325
        • Medical Oncology and Hematology Associates - West Des Moines
      • Des Moines, Iowa, 미국, 50309
        • CCOP - Iowa Oncology Research Association
      • Des Moines, Iowa, 미국, 50309
        • John Stoddard Cancer Center at Iowa Methodist Medical Center
      • Des Moines, Iowa, 미국, 50309
        • Medical Oncology and Hematology Associates at John Stoddard Cancer Center
      • Des Moines, Iowa, 미국, 50314
        • Medical Oncology and Hematology Associates at Mercy Cancer Center
      • Des Moines, Iowa, 미국, 50314
        • Mercy Cancer Center at Mercy Medical Center - Des Moines
      • Des Moines, Iowa, 미국, 50316
        • John Stoddard Cancer Center at Iowa Lutheran Hospital
      • Ottumwa, Iowa, 미국, 52501
        • McCreery Cancer Center at Ottumwa Regional
      • Sioux City, Iowa, 미국, 51101
        • Siouxland Hematology-Oncology Associates, LLP
      • Sioux City, Iowa, 미국, 51102
        • Mercy Medical Center - Sioux City
      • Sioux City, Iowa, 미국, 51104
        • St. Luke's Regional Medical Center
    • Kansas
      • Chanute, Kansas, 미국, 66720
        • Cancer Center of Kansas, PA - Chanute
      • Dodge City, Kansas, 미국, 67801
        • Cancer Center of Kansas, PA - Dodge City
      • El Dorado, Kansas, 미국, 67042
        • Cancer Center of Kansas, PA - El Dorado
      • Fort Scott, Kansas, 미국, 66701
        • Cancer Center of Kansas - Fort Scott
      • Independence, Kansas, 미국, 67301
        • Cancer Center of Kansas-Independence
      • Kingman, Kansas, 미국, 67068
        • Cancer Center of Kansas, PA - Kingman
      • Lawrence, Kansas, 미국, 66044
        • Lawrence Memorial Hospital
      • Liberal, Kansas, 미국, 67901
        • Cancer Center of Kansas, PA - Liberal
      • Newton, Kansas, 미국, 67114
        • Cancer Center of Kansas, PA - Newton
      • Parsons, Kansas, 미국, 67357
        • Cancer Center of Kansas, PA - Parsons
      • Pratt, Kansas, 미국, 67124
        • Cancer Center of Kansas, PA - Pratt
      • Salina, Kansas, 미국, 67401
        • Cancer Center of Kansas, PA - Salina
      • Wellington, Kansas, 미국, 67152
        • Cancer Center of Kansas, PA - Wellington
      • Wichita, Kansas, 미국, 67208
        • Cancer Center of Kansas, PA - Medical Arts Tower
      • Wichita, Kansas, 미국, 67214
        • Cancer Center of Kansas, PA - Wichita
      • Wichita, Kansas, 미국, 67214
        • CCOP - Wichita
      • Wichita, Kansas, 미국, 67214
        • Via Christi Cancer Center at Via Christi Regional Medical Center
      • Wichita, Kansas, 미국, 67208
        • Associates in Womens Health, PA - North Review
      • Winfield, Kansas, 미국, 67156
        • Cancer Center of Kansas, PA - Winfield
    • Michigan
      • Adrian, Michigan, 미국, 49221
        • Hickman Cancer Center at Bixby Medical Center
      • Ann Arbor, Michigan, 미국, 48106-0995
        • Saint Joseph Mercy Cancer Center
      • Ann Arbor, Michigan, 미국, 48106
        • CCOP - Michigan Cancer Research Consortium
      • Battle Creek, Michigan, 미국, 49017
        • Battle Creek Health System Cancer Care Center
      • Dearborn, Michigan, 미국, 48123-2500
        • Oakwood Cancer Center at Oakwood Hospital and Medical Center
      • Escanaba, Michigan, 미국, 49431
        • Green Bay Oncology, Limited - Escanaba
      • Flint, Michigan, 미국, 48503
        • Hurley Medical Center
      • Flint, Michigan, 미국, 48503
        • Genesys Hurley Cancer Institute
      • Grand Rapids, Michigan, 미국, 49503
        • Butterworth Hospital at Spectrum Health
      • Grand Rapids, Michigan, 미국, 49503
        • CCOP - Grand Rapids
      • Grand Rapids, Michigan, 미국, 49503
        • Lacks Cancer Center at Saint Mary's Health Care
      • Grosse Pointe Woods, Michigan, 미국, 48236
        • Van Elslander Cancer Center at St. John Hospital and Medical Center
      • Iron Mountain, Michigan, 미국, 49801
        • Dickinson County Healthcare System
      • Jackson, Michigan, 미국, 49201
        • Foote Memorial Hospital
      • Lansing, Michigan, 미국, 48912-1811
        • Sparrow Regional Cancer Center
      • Livonia, Michigan, 미국, 48154
        • St. Mary Mercy Hospital
      • Monroe, Michigan, 미국, 48162
        • Community Cancer Center of Monroe
      • Monroe, Michigan, 미국, 48162
        • Mercy Memorial Hospital - Monroe
      • Muskegon, Michigan, 미국, 49444
        • Mercy General Health Partners
      • Pontiac, Michigan, 미국, 48341-2985
        • St. Joseph Mercy Oakland
      • Port Huron, Michigan, 미국, 48060
        • Mercy Regional Cancer Center at Mercy Hospital
      • Reed City, Michigan, 미국, 49677
        • Spectrum Health Reed City Hospital
      • Saginaw, Michigan, 미국, 48601
        • Seton Cancer Institute at Saint Mary's - Saginaw
      • Saint Joseph, Michigan, 미국, 49085
        • Lakeside Cancer Specialists, PLLC
      • Saint Joseph, Michigan, 미국, 49085
        • Lakeland Regional Cancer Care Center - St. Joseph
      • Traverse City, Michigan, 미국, 49684
        • Munson Medical Center
      • Warren, Michigan, 미국, 48093
        • St. John Macomb Hospital
    • Minnesota
      • Bemidji, Minnesota, 미국, 56601
        • MeritCare Bemidji
      • Duluth, Minnesota, 미국, 55805
        • CCOP - Duluth
      • Duluth, Minnesota, 미국, 55805
        • Miller - Dwan Medical Center
      • Duluth, Minnesota, 미국, 55805-1983
        • Essentia Health - Duluth Clinic
      • Rochester, Minnesota, 미국, 55905
        • Mayo Clinic Cancer Center
    • Missouri
      • Springfield, Missouri, 미국, 65804
        • St. John's Regional Health Center
      • Springfield, Missouri, 미국, 65807
        • Hulston Cancer Center at Cox Medical Center South
      • Springfield, Missouri, 미국, 65804
        • CCOP - Cancer Research for the Ozarks
    • Montana
      • Billings, Montana, 미국, 59101
        • CCOP - Montana Cancer Consortium
      • Billings, Montana, 미국, 59101
        • St. Vincent Healthcare Cancer Care Services
      • Billings, Montana, 미국, 59107-7000
        • Billings Clinic - Downtown
      • Billings, Montana, 미국, 59102
        • Hematology-Oncology Centers of the Northern Rockies - Billings
      • Bozeman, Montana, 미국, 59715
        • Bozeman Deaconess Cancer Center
      • Butte, Montana, 미국, 59701
        • St. James Healthcare Cancer Care
      • Great Falls, Montana, 미국, 59405
        • Sletten Cancer Institute at Benefis Healthcare
      • Helena, Montana, 미국, 59601
        • St. Peter's Hospital
      • Kalispell, Montana, 미국, 59901
        • Kalispell Regional Medical Center
      • Missoula, Montana, 미국, 59807-7877
        • Montana Cancer Specialists at Montana Cancer Center
      • Missoula, Montana, 미국, 59807
        • Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
    • North Dakota
      • Bismarck, North Dakota, 미국, 58501
        • Medcenter One Hospital Cancer Care Center
      • Bismarck, North Dakota, 미국, 58501
        • Mid Dakota Clinic, PC
      • Bismarck, North Dakota, 미국, 58502
        • St. Alexius Medical Center Cancer Center
      • Fargo, North Dakota, 미국, 58122
        • CCOP - MeritCare Hospital
      • Fargo, North Dakota, 미국, 58102
        • MeritCare Broadway
    • Ohio
      • Bowling Green, Ohio, 미국, 43402
        • Wood County Oncology Center
      • Dayton, Ohio, 미국, 45405
        • Grandview Hospital
      • Dayton, Ohio, 미국, 45406
        • Good Samaritan Hospital
      • Dayton, Ohio, 미국, 45409
        • David L. Rike Cancer Center at Miami Valley Hospital
      • Dayton, Ohio, 미국, 45415
        • Samaritan North Cancer Care Center
      • Dayton, Ohio, 미국, 45420
        • CCOP - Dayton
      • Elyria, Ohio, 미국, 44035
        • Community Cancer Center
      • Elyria, Ohio, 미국, 44035
        • Hematology Oncology Center
      • Findlay, Ohio, 미국, 45840
        • Blanchard Valley Medical Associates
      • Franklin, Ohio, 미국, 45005-1066
        • Middletown Regional Hospital
      • Greenville, Ohio, 미국, 45331
        • Wayne Hospital
      • Kettering, Ohio, 미국, 45429
        • Charles F. Kettering Memorial Hospital
      • Lima, Ohio, 미국, 45804
        • Lima Memorial Hospital
      • Maumee, Ohio, 미국, 43537-1839
        • Northwest Ohio Oncology Center
      • Oregon, Ohio, 미국, 43616
        • St. Charles Mercy Hospital
      • Oregon, Ohio, 미국, 43616
        • Toledo Clinic - Oregon
      • Sylvania, Ohio, 미국, 43560
        • Flower Hospital Cancer Center
      • Tiffin, Ohio, 미국, 44883
        • Mercy Hospital of Tiffin
      • Toledo, Ohio, 미국, 43608
        • St. Vincent Mercy Medical Center
      • Toledo, Ohio, 미국, 43606
        • Toledo Hospital
      • Toledo, Ohio, 미국, 43614
        • Medical University of Ohio Cancer Center
      • Toledo, Ohio, 미국, 43617
        • CCOP - Toledo Community Hospital
      • Toledo, Ohio, 미국, 43623
        • Toledo Clinic, Incorporated - Main Clinic
      • Toledo, Ohio, 미국, 43623
        • St. Anne Mercy Hospital
      • Troy, Ohio, 미국, 45373-1300
        • UVMC Cancer Care Center at Upper Valley Medical Center
      • Wauseon, Ohio, 미국, 43567
        • Fulton County Health Center
      • Xenia, Ohio, 미국, 45385
        • Ruth G. McMillan Cancer Center at Greene Memorial Hospital
    • South Dakota
      • Sioux Falls, South Dakota, 미국, 57117-5039
        • Sanford Cancer Center at Sanford USD Medical Center
    • Virginia
      • Fredericksburg, Virginia, 미국, 22401
        • Fredericksburg Oncology, Incorporated
    • Wisconsin
      • Green Bay, Wisconsin, 미국, 54307-3508
        • St. Vincent Hospital Regional Cancer Center
      • Green Bay, Wisconsin, 미국, 54301-3526
        • Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
      • Green Bay, Wisconsin, 미국, 54303
        • Green Bay Oncology, Limited at St. Mary's Hospital
      • Green Bay, Wisconsin, 미국, 54303
        • St. Mary's Hospital Medical Center - Green Bay
      • Manitowoc, Wisconsin, 미국, 54221-1450
        • Holy Family Memorial Medical Center Cancer Care Center
      • Marinette, Wisconsin, 미국, 54143
        • Bay Area Cancer Care Center at Bay Area Medical Center
      • Oconto Falls, Wisconsin, 미국, 54154
        • Green Bay Oncology, Limited - Oconto Falls
      • Sheboygan, Wisconsin, 미국, 53081
        • St. Nicholas Hospital
      • Sturgeon Bay, Wisconsin, 미국, 54235
        • Green Bay Oncology, Limited - Sturgeon Bay

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria

  • Histological confirmation of metastatic adenocarcinoma, poorly differentiated non-small cell carcinoma, or poorly differentiated squamous carcinoma
  • Adequate FFPE tissue or re-biopsy planned after registration but prior to treatment
  • Measurable disease as defined; for patients having only lesions measuring at least 1 cm to =< 2 cm must use spiral computed tomography (CT) imaging for both pre- and post-treatment tumor assessments; disease that has received prior radiation (performed for palliative reasons) cannot be used for measurable disease
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Hemoglobin (Hgb) >= 9.0 g/dL
  • Absolute neutrophil count (ANC) >= 1,500/uL
  • Platelet count >= 100,000/uL
  • Total bilirubin =< upper limits of normal (ULN); if liver metastases are present, total bilirubin =< 2 x ULN
  • Aspartate aminotransferase (AST) =< 2.5 x ULN; if liver metastases are present, AST =< 5 x ULN
  • Creatinine =< 1.25 x ULN; if > 1.25 x ULN calculated creatinine clearance must be >= 60 ml/min
  • Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
  • Provide informed written consent
  • Willingness to return to NCCTG enrolling institution for follow-up
  • Willingness to abstain from eating grapefruit or drinking grapefruit juice for the duration of the study

Exclusion Criteria

  • Any of the following:

    • Pregnant women
    • Nursing women
    • Men or women of childbearing potential who are unwilling to employ adequate contraception; note: adequate contraception must be used throughout the trial and for 8 weeks after the last dose of RAD001, by both sexes
  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens

  • History of any of the following:

    • Known to be human immunodeficiency virus (HIV) positive
    • Known prior/current history of hepatitis related to hepatitis B or hepatitis C

  • Uncontrolled intercurrent illness including, but not limited to the following:

    • Ongoing or active infection (acute or chronic)
    • Symptomatic congestive heart failure
    • Unstable angina pectoris
    • Cardiac arrhythmia
    • Severely impaired lung function
    • Uncontrolled diabetes as defined by fasting serum glucose > 1.5 x ULN (note: optimal glycemic control should be achieved before starting trial therapy)
    • Liver disease such as cirrhosis or severe hepatic impairment
    • Psychiatric illness/social situations that would limit compliance with study requirements
  • Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm =< 4 weeks prior to registration
  • Other active malignancy =< 5 years prior to registration; EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of the cervix; NOTE: if there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer
  • Untreated brain metastases; NOTE: patients with treated, stable brain metastases for at least 12 weeks prior to study entry are eligible for enrollment
  • Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)
  • Active, bleeding diathesis
  • Receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent; topical or inhaled corticosteroids are allowed
  • Currently on enzyme inducing anti-convulsants (EIACs) or other strong inducers or strong inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)
  • Current use of warfarin (Coumadin); EXCEPTION: current use of low-molecular weight heparin is allowed
  • Known to be HIV positive
  • Inoculated with live attenuated vaccines =< 2 weeks prior to registration; note: close contact with those who have received attenuated live vaccines should be avoided during treatment with everolimus; examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin (BCG), yellow fever, varicella and TY21a typhoid vaccines
  • =< 4 weeks from major surgery; note: for this study, diagnostic laparoscopy (without other intervention) and/or biopsies (needle aspirate, core biopsy, open biopsy, etc.) are not considered major surgery

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Treatment (carboplatin, paclitaxel, and everolimus)
Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Patients also receive everolimus PO QD on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
의약품: 파클리탁셀
주어진 IV
의약품: 카보플라틴
주어진 IV
의약품: 에버로리무스
주어진 PO

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Percentage of Participants With Confirmed Tumor Responses
기간: First 6 Cycles of treatment (an average of 6 months)

Confirmed tumor response was defined to be either a complete response (CR) or partial response (PR) noted as the objective status on 2 consecutive evaluations at least 4 weeks apart.

Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria:

  • Complete Response (CR): disappearance of all target lesions;
  • Partial Response (PR) 30% decrease in sum of longest diameter of target lesions;
First 6 Cycles of treatment (an average of 6 months)

2차 결과 측정

결과 측정
측정값 설명
기간
Overall Survival
기간: Time from registration to death or last follow-up (up to 3 years)
Overall survival was defined as the time from study enrollment to the time of death from any cause or last follow-up.
Time from registration to death or last follow-up (up to 3 years)
Progression-free Survival
기간: Time from registration to the disease progression or death (up to 3 years)
The progression-free survival (PFS) was defined as the time from date of registration to the documentation of disease progression or death as a result of any cause, whichever comes first.
Time from registration to the disease progression or death (up to 3 years)
Duration of Response
기간: Up to 3 years
Duration of response was defined for all evaluable participants who have achieved an objective response as the date at which the participant's objective status is first noted to be either CR or PR to the date progression is documented.
Up to 3 years
Time to Treatment Failure
기간: Up to 3 years
Time to treatment failure was defined to be the time from the date of registration to the date at which the participant is removed from treatment due to progression, adverse events, or refusal.
Up to 3 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

Alliance for Clinical Trials in Oncology

협력자

National Cancer Institute (NCI)

수사관

  • 연구 의자: Matthew P. Goetz, MD, Mayo Clinic

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2009년 9월 1일

기본 완료 (실제)

2012년 12월 1일

연구 완료 (실제)

2013년 8월 1일

연구 등록 날짜

최초 제출

2009년 7월 8일

QC 기준을 충족하는 최초 제출

2009년 7월 8일

처음 게시됨 (추정)

2009년 7월 10일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2017년 3월 21일

QC 기준을 충족하는 마지막 업데이트 제출

2017년 2월 16일

마지막으로 확인됨

2017년 2월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

  • NCCTG-N0871
  • NCI-2011-01926 (레지스트리 식별자: CTRP (Clinical Trials Reporting System))
  • CDR0000643361 (레지스트리 식별자: PDQ (Physician Data Query))

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

Carcinoma of Unknown Primary Origin에 대한 임상 시험

파클리탁셀에 대한 임상 시험

유사한 임상시험 검색

스폰서 및 공동 작업자

건강 상태

약물 개입

CROs by country

CROs in Kyrgyzstan

정황

희귀 질병

약물 개입

식이 보충제

스폰서 / 협력자

위치

구독하다